|
货号 | 品名 | 规格 | 包装 | 单价 | 货期 | 库存 |
JD200512094618 | 维多珠单抗 | 99.64% | 5mg | 17600元 | 咨询客服 | 3天 |
JD200512094431 | 维多珠单抗 | 99.64% | 1mg | 5800元 | 咨询客服 | 3天 |
性状: | Vedolizumab是一种靶向α4β7整联蛋白 (integrin) 的人源化单克隆抗体,用来治疗溃疡性结肠炎和克罗恩病。 |
质量标准: | Description Vedolizumab is a humanized monoclonal antibody that targets the α4β7 integrin for the treatment of ulcerative colitis and Crohn's disease. IC50 & Target |
贮存: | References [1]. Soler D, et al. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrintherapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009 Sep;330(3):864-75. [2]. Singh H, et al. Vedolizumab: A novel anti-integrin drug for treatment of inflammatory bowel disease. J Nat Sci Biol Med. 2016 Jan-Jun;7( |